AGO2 and hepatocellular carcinoma: For instance, we could employ RNA pull-down combined with dual-luciferase reporter assays to validate the specific binding between circ_0058189 and miR-130a-3p; utilize AGO2-RIP experiments to confirm the direct targeting of EOGT mRNA by miR-130a-3p; and establish patient-derived xenograft (PDX) models coupled with liquid biopsy cohorts to verify the clinical translational potential of this axis in sorafenib resistance in HCC.